Creso Competitors

Delisted . USA . 
Stock . Creso Pharma Limited
COPHFDelisted Stock  USD 0.12  0.00  0.00%   
Creso Pharma Limited competes with Bionoid Pharma; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Creso Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Creso Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Creso Pharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.120.120.12
Details
Intrinsic
Valuation
LowRealHigh
0.100.100.13
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Creso Pharma. Your research has to be compared to or analyzed against Creso Pharma's peers to derive any actionable benefits. When done correctly, Creso Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Creso Pharma Limited.

Creso Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Creso Pharma and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Creso and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Creso Pharma Limited does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CTTH
+ 0.36
CNTRF
SHMN
+ 0.35
DKSC
CTTH
+ 0.28
SHMN
ABTI
+ 0.27
SHMN
CTTH
+ 0.23
CPHRF
BINP
+ 0.21
RMRK
  
High negative correlations   
CNTRF
- 0.19
DKSC
BINP
- 0.19
DKSC
ABTI
- 0.17
CNTRF
CTTH
- 0.16
BINP
DKSC
- 0.16
RMRK
CPHRF
- 0.09
RMRK

Risk-Adjusted Indicators

There is a big difference between Creso Pink Sheet performing well and Creso Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Creso Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CNNXF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
RMRK  8.78  1.15  0.04 (5.37) 9.96 
(33.33)
 33.33 
(25.00)
 58.33 
DKSC  8.85  1.34  0.11 (12.09) 7.98 
(14.61)
 20.00 
(14.29)
 48.57 
FWDG  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
SHMN  5.56 (0.74) 0.00 (0.86) 0.00 
 0.00 
 11.11 
(11.11)
 38.18 
BINP  7.94  3.03  0.00 (0.21) 0.00 
 0.00 
 25.00 
 0.00 
 109.09 
CNTRF  10.20  1.82  0.03 (0.25) 14.20 
(113.51)
 0.00 
(33.33)
 213.33 
CPHRF  4.43  0.74  0.07  0.74  7.83 
(6.87)
 4.58 
(3.64)
 133.83 
CTTH  8.80  1.02  0.08  0.32  10.76 
(17.45)
 16.67 
(16.18)
 210.66 
ABTI  8.23  2.14  0.00 (1.82) 0.00 
 0.00 
 32.76 
(2.44)
 171.75 
All Fundamental Data

Creso Pharma Competitive Analysis

The better you understand Creso Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Creso Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Creso Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
COPHF RMRK DKSC SHMN BINP CNTRF CPHRF CTTH ABTI GRVE
 0.00 
 0.12 
Creso
 25.00 
 0.0003 
Rimrock
 8.33 
 0 
Dakshidin
 0.00 
 0.0008 
Sohm
 8.00 
 0.27 
Bionoid
 55.17 
 0.05 
Centr
 0.00 
 2.57 
Cipher
 0.20 
 0.05 
CTT
 32.76 
 0.01 
Alterola
 75.51 
 0 
Groove
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Out of control
Very steady
Out of control
Out of control
Very steady
Out of control
Out of control
Out of control
Market Performance
(90 Days Performance)
Very Weak
Modest
OK
Very Weak
OK
Modest
Very Weak
Modest
Modest
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Above Average
Dangerous
Above Average
Quite High
Dangerous
Quite High
Average
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Current Ratio
2.68
0.01
N/A
1.22
0.07
7.02
2.51
5.01
0.1
0.08
Net Asset
29.31 M
396.96 K
N/A
2.91 M
N/A
5.89 M
51.65 M
186.54 K
12.13 K
N/A
Profit Margin
-2.41
N/A
N/A
-0.87
N/A
N/A
0.45
N/A
N/A
N/A
EBITDA
(28.06 M)
(452.96 K)
N/A
(1.01 M)
(385.71 K)
(5.28 M)
11.85 M
N/A
(6.47 M)
(82.7 K)
Operating Margin
-2.39
N/A
N/A
-0.87
-4.22
-4.85
0.57
N/A
N/A
-50.62
Current Valuation
24.06 M
369.24 K
N/A
4.99 M
3.81 M
20.12 M
46.13 M
18.87 M
68.08 M
1.41 M
Price To Book
0.36
7.41
N/A
N/A
N/A
11.34
1.63
10.64
6.29
N/A
Retained Earnings
N/A
(4.47 M)
(940 K)
(238.52 M)
N/A
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
5 K
N/A
1.75 M
N/A
N/A
N/A
N/A
N/A
N/A
Beta
2.61
1.01
-28.84
0.64
-2.12
-0.44
1.03
1.14
-6.65
1.36
Number Of Employees
19
2
3
145
5
4
26
15
6
1
Shares Outstanding
2 B
780.76 M
N/A
N/A
42.28 M
97.65 M
25.12 M
21.32 M
807.05 M
28.29 M
Cash Flow From Operations
(22.38 M)
(284.62 K)
(6.85 K)
(851.19 K)
(357.62 K)
(5.57 M)
13.81 M
(145.16 K)
44.34 K
(72.91 K)
Total Debt
3.26 M
N/A
N/A
3.5 M
64.5 K
31.63 K
507 K
87.62 K
251.18 K
169.2 K
Return On Equity
-0.67
-14.25
N/A
N/A
N/A
-2.51
0.24
-4.49
-1.27
N/A
Z Score
9.0
-19.9
-2.8
N/A
N/A
N/A
75.6
N/A
N/A
6.0
Return On Asset
-0.38
-0.69
N/A
-0.25
-1.64
-0.91
0.15
-1.54
-0.67
-4.77
Book Value Per Share
0.021
N/A
N/A
-0.001
-29.92
0.014
1.77
0.035
0.013
-0.009
Number Of Shares Shorted
N/A
N/A
N/A
N/A
N/A
N/A
11.43 K
N/A
N/A
N/A
Current Liabilities
N/A
434 K
259 K
1.4 M
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
29.31 M
396.96 K
359 K
2.91 M
N/A
5.89 M
51.65 M
186.54 K
12.13 K
N/A
Debt To Equity
0.24
1.08
N/A
-1.12
N/A
0.12
0.012
0.12
0.023
9.0
Short Ratio
N/A
N/A
N/A
N/A
N/A
N/A
0.97
N/A
N/A
N/A
Target Price
N/A
N/A
N/A
N/A
N/A
N/A
5.59
N/A
N/A
N/A
Market Capitalization
49.92 M
312.3 K
50 K
861.17 K
42.28 M
26.67 M
64.32 M
16.17 M
39.55 M
1.73 M
Price To Earning
N/A
-0.08
N/A
-0.05
N/A
26.92
15.54
-3.0
N/A
N/A
Price To Sales
4.68
N/A
N/A
0.91
540.76
18.14
3.28
N/A
N/A
197.53
Net Income
(30.03 M)
(851.33 K)
(147.4 K)
(1.02 M)
(1.62 M)
484.94 K
7.76 M
(1.38 M)
(6.47 M)
(290.46 K)
Earnings Per Share
-0.019
-0.012
N/A
-0.002
-46.27
0.01
0.36
-0.08
-0.008
-0.022
Shares Owned By Insiders
26.99
N/A
N/A
N/A
N/A
31.61
44.12
N/A
N/A
N/A
Revenue
6.22 M
N/A
N/A
1.96 M
92.26 K
1.85 M
21.94 M
40 K
N/A
8.05 K
Working Capital
N/A
(429 K)
N/A
353 K
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
3.14 M
2.22 K
N/A
182.56 K
127
3.86 M
24.19 M
32.12 K
61.54 K
99.38 K
Cash Per Share
N/A
N/A
N/A
N/A
N/A
0.04
0.96
N/A
N/A
N/A
Gross Profit
(400.39 K)
(161.9 K)
N/A
333.87 K
47.48 K
533.4 K
18.26 M
N/A
N/A
8.05 K
Day Typical Price
0.12
3.0E-4
0.0013
8.0E-4
0.27
0.0538
2.57
0.0463
0.0077
0.0012
Accumulation Distribution
N/A
N/A
0.0769
N/A
N/A
N/A
N/A
0.3
N/A
N/A
Market Facilitation Index
N/A
N/A
1.0E-4
N/A
N/A
N/A
N/A
0.0159
N/A
N/A
Daily Balance Of Power
0.0
(9,223,372,036,855)
1.0
0.0
9.2 T
(9,223,372,036,855)
0.0
(0.01)
9.2 T
(9,223,372,036,855)
Period Momentum Indicator
N/A
(0.0001)
1.0E-4
N/A
0.02
(0.07)
N/A
(0.0001)
0.0019
(0)
Rate Of Daily Change
1.0
0.75
1.08
1.0
1.08
0.45
1.0
1.0
1.33
0.24
Day Median Price
0.12
3.0E-4
0.0013
8.0E-4
0.27
0.0538
2.57
0.045
0.0077
0.0012
Price Action Indicator
N/A
(0.00005)
1.0E-4
N/A
0.01
(0.03)
N/A
0.0039
0.001
(0)
Coefficient Of Variation
N/A
1360.66
838.46
(1,203)
895.86
2142.25
1667.24
1722.07
1019.73
(582.89)
Mean Deviation
N/A
8.78
8.85
5.56
7.94
10.2
4.43
8.8
8.23
4.21
Jensen Alpha
N/A
1.15
1.34
(0.74)
3.03
1.82
0.7406
1.02
2.14
(2.17)
Total Risk Alpha
N/A
(0.80)
(0.07)
(1.65)
(0.25)
(2.24)
(0.93)
(1.65)
(0.56)
(3.35)
Sortino Ratio
N/A
0.0391
0.1075
N/A
N/A
0.0292
0.0685
0.0826
N/A
N/A
Downside Variance
N/A
703.13
133.37
N/A
N/A
1798.05
121.02
261.3
N/A
N/A
Standard Deviation
N/A
15.46
11.25
7.92
19.11
28.71
14.23
24.72
20.91
11.28
Kurtosis
N/A
0.9513
(0.41)
0.0714
16.99
14.63
30.43
43.46
19.68
31.56
Potential Upside
N/A
33.33
20.0
11.11
25.0
N/A
4.58
16.67
32.76
N/A
Treynor Ratio
N/A
(5.37)
(12.09)
(0.86)
(0.21)
(0.25)
0.737
0.3173
(1.82)
(0.78)
Maximum Drawdown
N/A
58.33
48.57
38.18
109.09
213.33
133.83
210.66
171.75
94.51
Variance
N/A
239.07
126.63
62.68
365.19
824.37
202.62
611.05
437.43
127.27
Market Risk Adjusted Performance
N/A
(5.36)
(12.08)
(0.85)
(0.20)
(0.24)
0.747
0.3273
(1.81)
(0.77)
Risk Adjusted Performance
N/A
0.0628
0.0958
(0.05)
0.0906
0.0436
0.053
0.0518
0.0808
(0.12)
Skewness
N/A
0.5993
0.4221
0.1997
2.28
2.88
3.87
5.71
2.78
(5.28)
Semi Deviation
N/A
9.96
7.98
N/A
N/A
14.2
7.83
10.76
N/A
N/A
Information Ratio
N/A
0.067
0.1104
(0.1)
0.1064
0.0432
0.0529
0.054
0.0933
(0.18)
Value At Risk
N/A
(25.00)
(14.29)
(11.11)
N/A
(33.33)
(3.64)
(16.18)
(2.44)
(9.26)
Expected Short fall
N/A
(33.33)
(14.61)
N/A
N/A
(113.51)
(6.87)
(17.45)
N/A
N/A
Downside Deviation
N/A
26.52
11.55
N/A
N/A
42.4
11.0
16.16
N/A
N/A
Semi Variance
N/A
99.29
63.76
N/A
N/A
201.64
61.3
115.86
N/A
N/A

Creso Pharma Competition Performance Charts

Five steps to successful analysis of Creso Pharma Competition

Creso Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Creso Pharma Limited in relation to its competition. Creso Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Creso Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Creso Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Creso Pharma Limited, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Creso Pharma position

In addition to having Creso Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Transportation Thematic Idea Now

Transportation
Transportation Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Transportation theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Transportation Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Consideration for investing in Creso Pink Sheet

If you are still planning to invest in Creso Pharma Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Creso Pharma's history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY